Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

Close menu
  • News
  • Products
  • Contact
    • Request More Information
    • Journalists
    • GDPR

    Evogene Schedules Second Quarter 2026 Financial Results Release

    Evogene Logo

    News provided by

    Evogene

    30 Jul, 2026, 14:00 IDT

    Share this article

    Share this article


    Zoom conference call scheduled for August 18, 2026, 9:00 AM ET

    REHOVOT, Israel, July 30, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the second quarter 2026, on Tuesday, August 18, 2026.

    Later that day, company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).

    To attend the conference, please register in advance:

    https://www.veidan-conferencing.com/evogene

    The entire conference will be available online on the company's website a few days after.

    About Evogene:

    Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products. At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.

    For more information, please visit www.evogene.com.

    Contact

    [email protected]
    Tel: +972-8-9311901

    Logo - https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg 

    SOURCE Evogene

    Modal title

    Also from this source

    Evogene Schedules Third Quarter 2026 Financial Results Release

    Evogene Schedules Third Quarter 2026 Financial Results Release

    Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules...

    Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program

    Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program

    Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in AI-driven generative design of small molecules ...

    More Releases From This Source

    Contact PR Newswire

    • +972-77-2005042
      from 8 AM - 11 PM IL

    Global Sites

    • APAC
    • APAC - Traditional Chinese
    • Asia
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany

     

    • India
    • Indonesia
    • Israel
    • Italy
    • Mexico
    • Middle East
    • Middle East - Arabic
    • Netherlands
    • Norway
    • Poland

     

    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom
    • United States

    Do not sell or share my personal information:

    • Submit via [email protected] 
    • Call Privacy toll-free: 877-297-8921
    Global Sites
    • Asia
    • Brazil
    • Canada
    • Csezh
    • Denmark
    • Finland
    • France
    • Germany
    • India
    • Israel
    • Italie
    • Mexico
    • Middle East
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom
    • United States
    +972-77-2005042
    from 8 AM - 11 PM IL
    • Terms of Use
    • Privacy Policy
    • Information Security Policy
    • Site Map
    • Cookie Settings
    Copyright © 2026 Cision US Inc.